CAS 1042672-97-8

N-[2-Methoxy-4-(4-morpholinyl)phenyl]-2-(3-pyridinyl)-4-thiazolecarboxamide

CAS : 1042672-97-8

Formule : C₂₀H₂₀N₄O₃S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 396.4628

Ref: IN-DA008TH1

IRAK inhibitor 6

CAS : 1042672-97-8

IRAK inhibitor 6

Degré de pureté : ≥98%

Masse moléculaire : 396.46g/mol

Ref: 54-BUP04163

IRAK inhibitor 6

CAS : 1042672-97-8

IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK-4, IC50: 160 nM).

Formule : C₂₀H₂₀N₄O₃S

Degré de pureté : 99.44%

Couleur et forme : Solid

Masse moléculaire : 396.46

Ref: TM-T5110

IRAK inhibitor 6

CAS : 1042672-97-8

Degré de pureté : ≥98%

Masse moléculaire : 396.126

Ref: 10-F863234

IRAK inhibitor 6

CAS : 1042672-97-8

IRAK inhibitor 6 is a kinase inhibitor that has been shown to be effective in both pre-clinical and clinical trials for cancer therapy. IRAK inhibitor 6 inhibits the activity of protein kinases, which are enzymes that regulate protein synthesis. This inhibition prevents the phosphorylation of proteins, which is required for their function. The inhibition of protein kinases by IRAK inhibitor 6 results in a decrease in cancer-related genes and an increase in normalizing proteins. In pre-clinical trials, this drug was shown to exhibit low toxicity and significant efficacy against cancers such as prostate cancer, colon cancer, and pancreatic cancer. In clinical trials, it was found to be safe at doses that were up to 10 times higher than the effective dose.

Formule : C₂₀H₂₀N₄O₃S

Degré de pureté : Min. 95%

Masse moléculaire : 396.46 g/mol

Ref: 3D-SRB67297